Instil Bio, Inc. Operating Lease Cost
Instil Bio, Inc. (TIL) reported Operating Lease Cost of $144.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-13
- Instil Bio, Inc. operating lease, cost for the quarter ending 2026-06-30 was $144.00K, a 63.64% decline year-over-year.
- Instil Bio, Inc. operating lease, cost for the quarter ending 2026-03-31 was $179.00K, a 57.58% decline year-over-year.
- Instil Bio, Inc. operating lease, cost for the quarter ending 2025-12-31 was $447.00K, a 105.05% increase year-over-year.
- Instil Bio, Inc. operating lease, cost for the quarter ending 2025-09-30 was $290.00K, a 68.60% increase year-over-year.
- Instil Bio, Inc. operating lease, cost for fiscal 2025 was $1.55M, a 18.25% increase from fiscal 2024.
- Instil Bio, Inc. operating lease, cost for fiscal 2024 was $1.31M, a 39.82% decline from fiscal 2023.
- Instil Bio, Inc. operating lease, cost for fiscal 2023 was $2.19M, a 54.97% decline from fiscal 2022.
- Instil Bio, Inc. operating lease, cost for fiscal 2022 was $4.85M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $144.00K 10-Q · filed 2026-08-13 | $323.00K 10-Q · filed 2026-08-13 | $770.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.06M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $179.00K 10-Q · filed 2026-05-15 | $626.00K derived: sum of 2 quarters · filed 2026-05-15 | $916.00K derived: sum of 3 quarters · filed 2026-05-15 | $1.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $447.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $737.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.13M derived: sum of 3 quarters · filed 2026-08-13 | $1.55M 10-K · filed 2026-03-27 |
| 2025-09-30 | $290.00K 10-Q · filed 2025-11-13 | $686.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.11M 10-Q · filed 2025-11-13 | $1.33M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $396.00K 10-Q · filed 2026-08-13 | $818.00K 10-Q · filed 2026-08-13 | $1.04M derived: sum of 3 quarters · filed 2026-08-13 | $1.21M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $422.00K 10-Q · filed 2026-05-15 | $640.00K derived: sum of 2 quarters · filed 2026-05-15 | $812.00K derived: sum of 3 quarters · filed 2026-05-15 | $1.35M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $218.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $390.00K derived: sum of 2 quarters · filed 2026-03-27 | $927.00K derived: sum of 3 quarters · filed 2026-03-27 | $1.31M 10-K · filed 2026-03-27 |
| 2024-09-30 | $172.00K 10-Q · filed 2025-11-13 | $709.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.10M 10-Q · filed 2025-11-13 | $1.42M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $537.00K 10-Q · filed 2025-08-13 | $925.00K 10-Q · filed 2025-08-13 | $1.24M derived: sum of 3 quarters · filed 2025-08-13 | $1.59M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $388.00K 10-Q · filed 2025-05-13 | $706.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.06M derived: sum of 3 quarters · filed 2025-05-13 | $1.36M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $669.00K derived: sum of 2 quarters · filed 2025-03-04 | $976.00K derived: sum of 3 quarters · filed 2025-03-04 | $2.19M 10-K · filed 2025-03-04 |
| 2023-09-30 | $351.00K 10-Q · filed 2024-11-13 | $658.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.87M 10-Q · filed 2024-11-13 | $2.90M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $307.00K 10-Q · filed 2024-08-13 | $1.52M 10-Q · filed 2024-08-13 | $2.54M derived: sum of 3 quarters · filed 2024-08-13 | $3.70M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.21M 10-Q · filed 2024-05-10 | $2.24M derived: sum of 2 quarters · filed 2024-05-10 | $3.39M derived: sum of 3 quarters · filed 2024-05-10 | $4.74M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.18M derived: sum of 2 quarters · filed 2024-03-21 | $3.53M derived: sum of 3 quarters · filed 2024-03-21 | $4.85M 10-K · filed 2024-03-21 |
| 2022-09-30 | $1.15M 10-Q · filed 2022-11-14 | $2.50M derived: sum of 2 quarters · filed 2022-11-14 | $3.82M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $1.35M 10-Q · filed 2022-08-12 | $2.67M 10-Q · filed 2022-08-12 | ||
| 2022-03-31 | $1.32M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |